Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 03, 2023 5:30pm

150 Views

Post# 35478750

RE:RE:RE:The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't

Expansion of Big Pharma's "sweet spot " to US $25 Billion falls in line with the perspective that the FTC will likely not review any M&A deal under US$ 23 Billion, as commented on before.

This places ONCY in a good position in having the company valued and acquired between $10 - $15 Billion.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects